Children's drug concept stocks are booming, and many R&D and production companies report net profits increase by more than 30%

According to news on October 9th, as of press time, Qianyuan Pharmaceuticals rose 3.
63%, Kangzhi Pharmaceuticals rose 3.
31%, Sunflower Pharmaceuticals rose 1.
88%, Calabash Baby rose 1.
69%, and Puli Pharmaceuticals rose 1.
45%.
In addition, Walter Dyne Also followed up
.
For a long time, children's medicines in our country have been faced with the problems of fewer children-specific varieties, fewer suitable dosage forms, and irregular use of medicines
.
Since the beginning of this year, with the release of a series of policies such as encouraging children's drug R&D and production, accelerating the approval of children's drug application, and the three-child policy, children's drug concept stocks have been on the move, and related children's drug R&D companies have also attracted the attention of the industry
.
It is understood that there are only more than 10 pharmaceutical companies specializing in children’s drugs in China.
Among the listed companies that are engaged in the R&D and production of children’s drugs are Sunflower Pharmaceutical, Gourd Baby, Kangzhi Pharmaceutical, Yabao Pharmaceutical, Jianmin Group, Poinsettia, Qianyuan Pharmaceutical, Puli Pharmaceuticals, Huat Dyne and other enterprises
.
As of now, the interim reports of these pharmaceutical companies have all disclosed that they have performed well overall, with the interim net profits of many companies increasing by more than 30%
.
Sunflower Pharmaceuticals: Net profit increased by nearly 30% year-on-year.
Sunflower Pharmaceuticals disclosed its interim report on August 26, 2021.
The company achieved total operating income of 2.
1 billion in the first half of 2021, a year-on-year increase of 31.
4%; net profit attributable to parent company was 310 million, a year-on-year increase 29.
6%; earnings per share is 0.
53 yuan
.
Huluwa: Net profit increased by 22.
11% year-on-year.
Huluwa disclosed its interim report on August 27, 2021.
The company's main operating income in the first half of the year was 631 million yuan, a year-on-year increase of 9.
67%; net profit attributable to the parent was 51.
915 million yuan, a year-on-year increase of 22.
11%; The share return is 0.
13 yuan
.
Kangzhi Pharmaceutical: Failed to maintain profitability On August 27, Kangzhi Pharmaceutical released the 2021 semi-annual report
.
The report shows that in the first half of 2021, Kangzhi Pharmaceutical's operating income was 424 million yuan, a year-on-year increase of 2.
97%; net profit attributable to the parent was -57.
637 million, compared with 7.
45 million in the same period last year, failing to maintain profitability
.
Yabao Pharmaceuticals: Net profit increased by 62.
7% Yabao Pharmaceuticals disclosed its interim report on August 21, 2021.
The company achieved total operating income of 1.
46 billion in the first half of 2021, a year-on-year increase of 27.
2%; net profit attributable to the parent was 99.
325 million, year-on-year An increase of 62.
7%; earnings per share was 0.
13 yuan
.
Jianmin Group: doubled net profit Jianmin Group’s 2021 interim report released in July showed that the company’s main operating income in the first half of the year was 1.
793 billion yuan, a year-on-year increase of 74.
5%; net profit attributable to the parent was 167 million yuan, a year-on-year increase of 192.
24%; A profit of 159 million yuan, a year-on-year increase of 203.
4%.
Poinsettia: net profit increased by 46.
61%.
Poinsettia released a semi-annual performance report on the evening of July 29, stating that the operating income for the first half of 2021 was about 953 million yuan; the net profit attributable to shareholders of listed companies was about 1.
18 Billion yuan, an increase of 46.
61% year-on-year; basic earnings per share were 0.
41 yuan
.
Qianyuan Pharmaceutical: Loss narrowed.
Qianyuan Pharmaceutical disclosed its interim report on August 28, 2021.
The company achieved total operating income of 460 million in the first half of 2021, a year-on-year increase of 16%; net profit attributable to the parent was -4.
119 million, the same period last year It was 75.
23 million yuan, and the loss narrowed
.
Basic earnings per share is -0.
02 yuan
.
Puli Pharmaceuticals: Net profit increased by 42.
06%.
On August 10, Puli Pharmaceuticals released its 2021 semi-annual report, showing that in the first half of the year, it achieved revenue of 623 million yuan, a year-on-year increase of 55.
11%; realized a net profit of 225 million yuan, a year-on-year increase of 42.
06%; The deduction of non-net profit was 219 million yuan, a year-on-year increase of 39.
27%
.
Walter Dyne: Net profit increased by 69.
8%.
Walter Dyne disclosed its semi-annual report on the evening of July 29.
In the first half of 2021, the company achieved operating income of 1.
011 billion yuan, a year-on-year increase of 21.
45%; net profit attributable to shareholders of listed companies 229 million yuan, an increase of 69.
8% year-on-year; basic earnings per share were 0.
98 yuan
.